Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 127

1.

Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma.

Usmani SZ, Nahi H, Mateos MV, van de Donk NWCJ, Chari A, Kaufman JL, Moreau P, Oriol A, Plesner T, Benboubker L, Hellemans P, Masterson T, Clemens PL, Luo M, Liu K, San-Miguel J.

Blood. 2019 Aug 22;134(8):668-677. doi: 10.1182/blood.2019000667. Epub 2019 Jul 3.

PMID:
31270103
2.

"Fine-tuning cytoreduction in resistant multiple myeloma - progress here, too"?

Plesner T.

Br J Haematol. 2019 Jun 19. doi: 10.1111/bjh.16061. [Epub ahead of print] No abstract available.

PMID:
31218675
3.

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.

Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Mace JR, Raje N, Attal M, Tiab M, Macro M, Frenzel L, Leleu X, Ahmadi T, Chiu C, Wang J, Van Rampelbergh R, Uhlar CM, Kobos R, Qi M, Usmani SZ; MAIA Trial Investigators.

N Engl J Med. 2019 May 30;380(22):2104-2115. doi: 10.1056/NEJMoa1817249.

PMID:
31141632
4.

Daratumumab for treatment of blastic plasmacytoid dendritic cell neoplasm. A single-case report.

Iversen KF, Holdgaard PC, Preiss B, Nyvold CG, Plesner T.

Haematologica. 2019 Sep;104(9):e432-e433. doi: 10.3324/haematol.2018.214635. Epub 2019 Apr 11. No abstract available.

5.

Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study.

Plesner T, Arkenau HT, Gay F, Minnema MC, Boccadoro M, Moreau P, Cavenagh J, Perrot A, Laubach JP, Krejcik J, Ahmadi T, de Boer C, Chen D, Chiu C, Schecter JM, Richardson PG.

Br J Haematol. 2019 Aug;186(3):e35-e39. doi: 10.1111/bjh.15879. Epub 2019 Mar 31. No abstract available.

PMID:
30931524
6.

High intratumoral expression of vimentin predicts histological transformation in patients with follicular lymphoma.

Madsen C, Lauridsen KL, Plesner TL, Monrad I, Honoré B, Hamilton-Dutoit S, d'Amore F, Ludvigsen M.

Blood Cancer J. 2019 Mar 18;9(4):35. doi: 10.1038/s41408-019-0197-5. No abstract available.

7.

High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.

Adams HC 3rd, Stevenaert F, Krejcik J, Van der Borght K, Smets T, Bald J, Abraham Y, Ceulemans H, Chiu C, Vanhoof G, Usmani SZ, Plesner T, Lonial S, Nijhof I, Lokhorst HM, Mutis T, van de Donk NWCJ, Sasser AK, Casneuf T.

Cytometry A. 2019 Mar;95(3):279-289. doi: 10.1002/cyto.a.23693. Epub 2018 Dec 11.

8.

Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study.

Madsen C, Clausen MR, Plesner TL, Pasanen A, Kuismanen T, Bentzen HH, Jørgensen JM, Sillesen IB, Himmelstrup BM, Rønnov-Jessen D, Jensen KR, Pettinger AM, Ludvigsen M, Leppä S, d'Amore FA.

Blood Adv. 2018 Jul 10;2(13):1562-1571. doi: 10.1182/bloodadvances.2018017673.

9.

Daratumumab for the Treatment of Multiple Myeloma.

Plesner T, Krejcik J.

Front Immunol. 2018 Jun 4;9:1228. doi: 10.3389/fimmu.2018.01228. eCollection 2018. Review.

10.

Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma.

Casneuf T, Xu XS, Adams HC 3rd, Axel AE, Chiu C, Khan I, Ahmadi T, Yan X, Lonial S, Plesner T, Lokhorst HM, van de Donk NWCJ, Clemens PL, Sasser AK.

Blood Adv. 2017 Oct 24;1(23):2105-2114. doi: 10.1182/bloodadvances.2017006866. eCollection 2017 Oct 24.

11.

Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab.

Krejcik J, Frerichs KA, Nijhof IS, van Kessel B, van Velzen JF, Bloem AC, Broekmans MEC, Zweegman S, van Meerloo J, Musters RJP, Poddighe PJ, Groen RWJ, Chiu C, Plesner T, Lokhorst HM, Sasser AK, Mutis T, van de Donk NWCJ.

Clin Cancer Res. 2017 Dec 15;23(24):7498-7511. doi: 10.1158/1078-0432.CCR-17-2027. Epub 2017 Oct 12.

12.

Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma.

Yan X, Clemens PL, Puchalski T, Lonial S, Lokhorst H, Voorhees PM, Usmani S, Richardson PG, Plesner T, Liu K, Orlowski RZ, Losic N, Jansson R, Ahmadi T, Lantz K, Ruixo JJP, Zhou H, Xu XS.

Clin Pharmacokinet. 2018 Apr;57(4):529-538. doi: 10.1007/s40262-017-0598-1.

13.

Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group.

Hillengass J, Moulopoulos LA, Delorme S, Koutoulidis V, Mosebach J, Hielscher T, Drake M, Rajkumar SV, Oestergaard B, Abildgaard N, Hinge M, Plesner T, Suehara Y, Matsue K, Withofs N, Caers J, Waage A, Goldschmidt H, Dimopoulos MA, Lentzsch S, Durie B, Terpos E.

Blood Cancer J. 2017 Aug 25;7(8):e599. doi: 10.1038/bcj.2017.78.

14.

The CLEC12A receptor marks human basophils: Potential implications for minimal residual disease detection in acute myeloid leukemia.

Toft-Petersen M, Stidsholt Roug A, Plesner T, Ebbesen L, Brown GD, Nederby L.

Cytometry B Clin Cytom. 2018 May;94(3):520-526. doi: 10.1002/cyto.b.21540. Epub 2017 Aug 11.

15.

Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study.

Sezer O, Beksac M, Hajek R, Sucak G, Cagirgan S, Linkesch W, Meltem Akay O, Gülbas Z, Nahi H, Plesner T, Snowden JA, Timurağaoğlu A, Dechow T, Lang A, Tuğlular T, Drach J, Armbrecht G, Potamianou A, Couturier C, Olie RA, Feys C, Allietta N, Terpos E.

Br J Haematol. 2017 Jul;178(1):61-71. doi: 10.1111/bjh.14637. Epub 2017 Apr 6.

PMID:
28382618
16.

Response to: Interference of daratumumab on the serum protein electrophoresis.

McCudden C, Axel AE, Slaets D, Dejoie T, Clemens P, Frans S, Bald J, Plesner T, Jacobs JF, van de Donk NW, Moreau P, Schecter JM, Ahmadi T, Sasser AK.

Clin Chem Lab Med. 2017 Feb 1;55(2):e29-e30. doi: 10.1515/cclm-2016-1026. No abstract available.

PMID:
27930366
17.

Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma.

Xu XS, Yan X, Puchalski T, Lonial S, Lokhorst HM, Voorhees PM, Plesner T, Liu K, Khan I, Jansson R, Ahmadi T, Ruixo JP, Zhou H, Clemens PL.

Clin Pharmacol Ther. 2017 Jun;101(6):721-724. doi: 10.1002/cpt.577. Epub 2017 Feb 13.

18.

The Danish National Multiple Myeloma Registry.

Gimsing P, Holmström MO, Klausen TW, Andersen NF, Gregersen H, Pedersen RS, Plesner T, Pedersen PT, Frederiksen M, Frølund U, Helleberg C, Vangsted A, de Nully Brown P, Abildgaard N.

Clin Epidemiol. 2016 Oct 25;8:583-587. eCollection 2016. Review.

19.

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Lisby S, Khokhar NZ, O'Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Moreau P; POLLUX Investigators.

N Engl J Med. 2016 Oct 6;375(14):1319-1331.

20.

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.

Plesner T, Arkenau HT, Gimsing P, Krejcik J, Lemech C, Minnema MC, Lassen U, Laubach JP, Palumbo A, Lisby S, Basse L, Wang J, Sasser AK, Guckert ME, de Boer C, Khokhar NZ, Yeh H, Clemens PL, Ahmadi T, Lokhorst HM, Richardson PG.

Blood. 2016 Oct 6;128(14):1821-1828. doi: 10.1182/blood-2016-07-726729. Epub 2016 Aug 16.

21.

Prophylactic immunoglobulin therapy in secondary immune deficiency - an expert opinion.

Agostini C, Blau IW, Kimby E, Plesner T.

Expert Rev Clin Immunol. 2016 Sep;12(9):921-6. doi: 10.1080/1744666X.2016.1208085. Epub 2016 Jul 14. Review.

PMID:
27415820
22.

Baseline bone involvement in multiple myeloma - a prospective comparison of conventional X-ray, low-dose computed tomography, and 18flourodeoxyglucose positron emission tomography in previously untreated patients.

Hinge M, Andersen KT, Lund T, Jørgensen HB, Holdgaard PC, Ormstrup TE, Østergaard LL, Plesner T.

Haematologica. 2016 Oct;101(10):e415-e418. Epub 2016 Jul 6. No abstract available.

23.

Bone healing in multiple myeloma: a prospective evaluation of the impact of first-line anti-myeloma treatment.

Hinge M, Andersen KT, Lund T, Jørgensen HB, Holdgaard PC, Ormstrup TE, Østergaard LL, Plesner T.

Haematologica. 2016 Oct;101(10):e419-e422. Epub 2016 Jun 30. No abstract available.

24.

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.

Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, Syed K, Liu K, van de Donk NW, Weiss BM, Ahmadi T, Lokhorst HM, Mutis T, Sasser AK.

Blood. 2016 Jul 21;128(3):384-94. doi: 10.1182/blood-2015-12-687749. Epub 2016 May 24.

25.

First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.

Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, Lange E, Köppler H, Kiehl M, Sökler M, Schlag R, Vehling-Kaiser U, Köchling G, Plöger C, Gregor M, Plesner T, Trneny M, Fischer K, Döhner H, Kneba M, Wendtner CM, Klapper W, Kreuzer KA, Stilgenbauer S, Böttcher S, Hallek M; international group of investigators; German CLL Study Group (GCLLSG).

Lancet Oncol. 2016 Jul;17(7):928-942. doi: 10.1016/S1470-2045(16)30051-1. Epub 2016 May 20.

PMID:
27216274
26.

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.

Usmani SZ, Weiss BM, Plesner T, Bahlis NJ, Belch A, Lonial S, Lokhorst HM, Voorhees PM, Richardson PG, Chari A, Sasser AK, Axel A, Feng H, Uhlar CM, Wang J, Khan I, Ahmadi T, Nahi H.

Blood. 2016 Jul 7;128(1):37-44. doi: 10.1182/blood-2016-03-705210. Epub 2016 May 23.

27.

Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.

Moreau P, van de Donk NW, Miguel JS, Lokhorst H, Nahi H, Ben-Yehuda D, Cavo M, Cook G, Delforge M, Einsele H, Zweegman S, Ludwig H, Driessen C, Palumbo A, Facon T, Plesner T, Dimopoulos M, Sondergeld P, Sonneveld P, Mateos MV.

Drugs. 2016 Jun;76(9):989-990. No abstract available.

PMID:
27206917
28.

Multiplex polymerase chain reaction-based prognostic models in diffuse large B-cell lymphoma patients treated with R-CHOP.

Green TM, Jensen AK, Holst R, Falgreen S, Bøgsted M, de Stricker K, Plesner T, Mourits-Andersen T, Frederiksen M, Johnsen HE, Pedersen LM, Møller MB.

Br J Haematol. 2016 Sep;174(6):876-86. doi: 10.1111/bjh.14138. Epub 2016 May 16.

PMID:
27196819
29.

Facilitated subcutaneous immunoglobulin administration (fSCIg): a new treatment option for patients with secondary immune deficiencies.

Blau IW, Conlon N, Petermann R, Nikolov N, Plesner T.

Expert Rev Clin Immunol. 2016 Jul;12(7):705-11. doi: 10.1080/1744666X.2016.1183482. Epub 2016 May 13.

PMID:
27156362
30.

Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.

Moreau P, van de Donk NW, San Miguel J, Lokhorst H, Nahi H, Ben-Yehuda D, Cavo M, Cook G, Delforge M, Einsele H, Zweegman S, Ludwig H, Driessen C, Palumbo A, Facon T, Plesner T, Dimopoulos M, Sondergeld P, Sonneveld P, Mateos MV.

Drugs. 2016 May;76(8):853-67. doi: 10.1007/s40265-016-0573-4. Review. Erratum in: Drugs. 2016 Jun;76(9):989-90.

PMID:
27113582
31.

Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference.

McCudden C, Axel AE, Slaets D, Dejoie T, Clemens PL, Frans S, Bald J, Plesner T, Jacobs JF, van de Donk NW, Moreau P, Schecter JM, Ahmadi T, Sasser AK.

Clin Chem Lab Med. 2016 Jun 1;54(6):1095-104. doi: 10.1515/cclm-2015-1031.

32.

Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.

Zweegman S, van der Holt B, Mellqvist UH, Salomo M, Bos GM, Levin MD, Visser-Wisselaar H, Hansson M, van der Velden AW, Deenik W, Gruber A, Coenen JL, Plesner T, Klein SK, Tanis BC, Szatkowski DL, Brouwer RE, Westerman M, Leys MR, Sinnige HA, Haukås E, van der Hem KG, Durian MF, Mattijssen EV, van de Donk NW, Stevens-Kroef MJ, Sonneveld P, Waage A.

Blood. 2016 Mar 3;127(9):1109-16. doi: 10.1182/blood-2015-11-679415. Epub 2016 Jan 22.

33.

Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma.

van de Donk NW, Moreau P, Plesner T, Palumbo A, Gay F, Laubach JP, Malavasi F, Avet-Loiseau H, Mateos MV, Sonneveld P, Lokhorst HM, Richardson PG.

Blood. 2016 Feb 11;127(6):681-95. doi: 10.1182/blood-2015-10-646810. Epub 2015 Dec 2. Review.

34.

Monoclonal antibodies in myeloma.

Sondergeld P, van de Donk NW, Richardson PG, Plesner T.

Clin Adv Hematol Oncol. 2015 Sep;13(9):599-609. Review.

PMID:
26452191
35.

Patient pools and the use of "patient means" are valuable tools in quality control illustrated by a bone-specific alkaline phosphatase assay.

Hinge M, Lund ED, Brandslund I, Plesner T, Madsen JS.

Clin Chem Lab Med. 2016 Mar;54(3):403-6. doi: 10.1515/cclm-2015-0308.

PMID:
26351926
36.

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.

Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, Minnema MC, Lassen U, Krejcik J, Palumbo A, van de Donk NW, Ahmadi T, Khan I, Uhlar CM, Wang J, Sasser AK, Losic N, Lisby S, Basse L, Brun N, Richardson PG.

N Engl J Med. 2015 Sep 24;373(13):1207-19. doi: 10.1056/NEJMoa1506348. Epub 2015 Aug 26.

37.

High-dose therapy improves the bone remodelling compartment canopy coverage and bone formation in multiple myeloma.

Hinge M, Delaisse JM, Plesner T, Clasen-Linde E, Salomo M, Andersen TL.

Br J Haematol. 2015 Nov;171(3):355-65. doi: 10.1111/bjh.13584. Epub 2015 Jul 27.

PMID:
26212720
38.

Immunostaining of skin biopsy adds no diagnostic value in MGUS-associated peripheral neuropathy.

Al-Zuhairy A, Schrøder HD, Plesner T, Abildgaard N, Sindrup SH.

J Neurol Sci. 2015 Feb 15;349(1-2):60-4. doi: 10.1016/j.jns.2014.12.026. Epub 2014 Dec 26.

PMID:
25582978
39.

Treatment Sequencing Survival Model for Patients with Multiple Myeloma Ineligible for Stem Cell Transplantation (SCT).

Heeg B, Van Agthoven M, van Beurden-Tan C, Liwing J, Mellqvist UH, Plesner T, Logman F, Aschan J, Einsele H, Treur M, Barendse M, Richardson PG, Palumbo A, Nahi H, Sonneveld P.

Value Health. 2014 Nov;17(7):A617-8. doi: 10.1016/j.jval.2014.08.2182. Epub 2014 Oct 26. No abstract available.

40.

European perspective on multiple myeloma treatment strategies in 2014.

Ludwig H, Sonneveld P, Davies F, Bladé J, Boccadoro M, Cavo M, Morgan G, de la Rubia J, Delforge M, Dimopoulos M, Einsele H, Facon T, Goldschmidt H, Moreau P, Nahi H, Plesner T, San-Miguel J, Hajek R, Sondergeld P, Palumbo A.

Oncologist. 2014 Aug;19(8):829-44. doi: 10.1634/theoncologist.2014-0042. Epub 2014 Jul 25. Review.

41.

The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network.

van de Donk NW, Palumbo A, Johnsen HE, Engelhardt M, Gay F, Gregersen H, Hajek R, Kleber M, Ludwig H, Morgan G, Musto P, Plesner T, Sezer O, Terpos E, Waage A, Zweegman S, Einsele H, Sonneveld P, Lokhorst HM; European Myeloma Network.

Haematologica. 2014 Jun;99(6):984-96. doi: 10.3324/haematol.2013.100552. Epub 2014 Mar 21. Review.

42.

Dosing related effects of zoledronic acid on bone markers and creatinine clearance in patients with multiple myeloma and metastatic breast cancer.

Søe K, Delaissé JM, Jakobsen EH, Hansen CT, Plesner T.

Acta Oncol. 2014 Apr;53(4):547-56. doi: 10.3109/0284186X.2013.844358. Epub 2013 Oct 28.

PMID:
24164102
43.

A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia.

Birgens H, Frederiksen H, Hasselbalch HC, Rasmussen IH, Nielsen OJ, Kjeldsen L, Larsen H, Mourits-Andersen T, Plesner T, Rønnov-Jessen D, Vestergaard H, Klausen TW, Schöllkopf C.

Br J Haematol. 2013 Nov;163(3):393-9. doi: 10.1111/bjh.12541. Epub 2013 Aug 24.

PMID:
23981017
44.

Is retention of zoledronic acid onto bone different in multiple myeloma and breast cancer patients with bone metastasis?

Søe K, Plesner T, Jakobsen EH, Hansen CT, Jørgensen HB, Delaissé JM.

J Bone Miner Res. 2013 Aug;28(8):1738-50. doi: 10.1002/jbmr.1897.

45.

Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia.

Gudbrandsdottir S, Birgens HS, Frederiksen H, Jensen BA, Jensen MK, Kjeldsen L, Klausen TW, Larsen H, Mourits-Andersen HT, Nielsen CH, Nielsen OJ, Plesner T, Pulczynski S, Rasmussen IH, Rønnov-Jessen D, Hasselbalch HC.

Blood. 2013 Mar 14;121(11):1976-81. doi: 10.1182/blood-2012-09-455691. Epub 2013 Jan 4.

46.

A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma.

Popat R, Plesner T, Davies F, Cook G, Cook M, Elliott P, Jacobson E, Gumbleton T, Oakervee H, Cavenagh J.

Br J Haematol. 2013 Mar;160(5):714-7. doi: 10.1111/bjh.12154. Epub 2012 Dec 4. No abstract available.

PMID:
23205612
47.

Treatment with bortezomib in multiple myeloma is associated with only a transient and brief increase of bone specific alkaline phosphatase.

Haidl F, Plesner T, Lund T.

Leuk Res. 2012 Oct;36(10):1296-9. doi: 10.1016/j.leukres.2012.06.007. Epub 2012 Jun 29.

PMID:
22748823
48.

Continuous lenalidomide treatment for newly diagnosed multiple myeloma.

Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, Gisslinger H, Wiktor-Jędrzejczak W, Zodelava M, Weisel K, Cascavilla N, Iosava G, Cavo M, Kloczko J, Bladé J, Beksac M, Spicka I, Plesner T, Radke J, Langer C, Ben Yehuda D, Corso A, Herbein L, Yu Z, Mei J, Jacques C, Dimopoulos MA; MM-015 Investigators.

N Engl J Med. 2012 May 10;366(19):1759-69. doi: 10.1056/NEJMoa1112704. Erratum in: N Engl J Med. 2012 Jul 19;367(3):285.

49.

Anti-myelin associated glycoprotein neuropathy responding to lenalidomide.

Larsen LH, Lund T, Vilholm OJ, Plesner T.

Leuk Res. 2011 Nov;35(11):e198-9. doi: 10.1016/j.leukres.2011.05.019. Epub 2011 Jul 28. No abstract available.

PMID:
21802139
50.

Multiple myeloma treatment strategies with novel agents in 2011: a European perspective.

Ludwig H, Beksac M, Bladé J, Cavenagh J, Cavo M, Delforge M, Dimopoulos M, Drach J, Einsele H, Facon T, Goldschmidt H, Harousseau JL, Hess U, Kropff M, Leal da Costa F, Louw V, Magen-Nativ H, Mendeleeva L, Nahi H, Plesner T, San-Miguel J, Sonneveld P, Udvardy M, Sondergeld P, Palumbo A.

Oncologist. 2011;16(4):388-403. doi: 10.1634/theoncologist.2010-0386. Epub 2011 Mar 26. Review.

Supplemental Content

Loading ...
Support Center